DV
Dividend Vision

CUE — Cue Biopharma, Inc.

Cue Biopharma, Inc. (CUE)

Total return is -90.2% over the past 8.6 years, 319.2 points behind SPY at 229.0%. Its deepest 1-year drawdown was 80.9%.

CUE is a single healthcare stock focused on biopharmaceutical development, rather than a diversified ETF fund. As an individual equity holding, it does not have a stated distribution rate, expense ratio, or regular dividend distributions typical of income-focused ETFs. This stock may appeal primarily to growth-oriented investors seeking exposure to the biotechnology sector rather than those prioritizing current income.

CUE key facts

Asset type
Stock
Asset class
Equity
Inception date
01/02/2018
Distribution frequency
None
Last close
$34.20
Market cap
$233,462,448
Average volume
157322.0
Beta
2.47
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.53